Sumitomo Pharma Co., Ltd.
4506・Prime Market・Pharmaceuticals
Governance
The company transitioned to a company with an audit and supervisory committee in June 2025. The Board of Directors consists of 10 members, including 5 independent outside directors, and has established a Nomination and Compensation Committee (with independent outside directors comprising a majority) as well as an Inter-Group Company Transactions Conflict of Interest Supervisory Committee to oversee conflicts of interest with the parent company.
Risk Management
The company has established the "SMP Group Risk Management Policy" and "Risk Management Regulations," under which the President oversees risk management for the entire group. Risks are classified into group-wide risks and business activity risks, with annual risk assessments conducted across all domestic and overseas departments, the results of which are regularly reported to the Board of Directors.
Shareholder Returns
FY2026 (ending March 2026) saw a significant increase in profit, but the year-end dividend was omitted in order to prioritize allocation of funds raised through the April 2026 public offering to R&D investment and financial soundness. The dividend for FY2027 (ending March 2027) also remains undecided, pending consideration of business performance trends. No share buyback was conducted.
Dividend Policy
The basic policy emphasizes appropriately distributing results underpinned by business performance, and in addition to stable dividends, aims to increase dividends in line with improved performance. As a general rule, dividends are paid twice a year: an interim dividend determined by resolution of the Board of Directors, and a year-end dividend determined by resolution of the General Meeting of Shareholders. In FY2026 (ending March 2026), core operating profit reached ¥105,908 million and profit attributable to owners of parent reached ¥106,865 million, representing a significant increase in profit; however, the company decided to prioritize allocation of funds raised through the public offering and other means conducted in April 2026 to accelerating investment centered on R&D and to strengthening financial soundness, and therefore the year-end dividend was omitted. The interim and year-end dividends for FY2027 (ending March 2027) remain undecided in light of the uncertain environment, including cost increases arising from pricing policy, tariff measures, and conflicts in the United States, and will be determined based on future business performance trends and other factors.
ESG
The company is advancing climate change initiatives in line with the TCFD recommendations (reducing Scope 1+2 GHG emissions by 42% by FY2030 compared to FY2020, and obtaining SBTi certification), while also setting human capital KPIs such as a female manager ratio of 20% or more (FY2027 target), a male childcare leave uptake rate of 100%, and improved engagement scores, and has obtained third-party assurance from KPMG AZSA Sustainability Co., Ltd.
Last updated: June 23, 2026